Per-Eric Lund
Overview
Explore the profile of Per-Eric Lund including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
409
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Klement G, Babich O, Larsson O, Lund P, Malmberg A, Sandberg L, et al.
Comb Chem High Throughput Screen
. 2012 Sep;
15(9):713-20.
PMID: 22934951
Congenital Insensitivity to Pain (CIP) is a loss of function mutation resulting in a truncated NaV1.7 protein, suggesting a pivotal role in pain signaling and rendering it an important pharmaceutical...
12.
Kers I, Csjernyik G, Macsari I, Nylof M, Sandberg L, Skogholm K, et al.
Bioorg Med Chem Lett
. 2012 Jul;
22(17):5618-24.
PMID: 22832315
Recent findings showing a relation between mutations in the Na(V)1.7 channel in humans and altered pain sensation has contributed to increase the attractiveness of this ion channel as target for...
13.
Macsari I, Besidski Y, Csjernyik G, Nilsson L, Sandberg L, Yngve U, et al.
J Med Chem
. 2012 Jul;
55(15):6866-80.
PMID: 22770500
The voltage-gated sodium channel Na(V)1.7 is believed to be a critical mediator of pain sensation based on clinical genetic studies and pharmacological results. Clinical utility of nonselective sodium channel blockers...
14.
Macsari I, Sandberg L, Besidski Y, Gravenfors Y, Ginman T, Bylund J, et al.
Bioorg Med Chem Lett
. 2011 Jun;
21(13):3871-6.
PMID: 21641215
Blocking of certain sodium channels is considered to be an attractive mechanism to treat chronic pain conditions. Phenyl isoxazole carbamate 1 was identified as a potent and selective Na(V)1.7 blocker....
15.
Dabrowski M, Dekermendjian K, Lund P, Krupp J, Sinclair J, Larsson O
CNS Neurol Disord Drug Targets
. 2008 Jun;
7(2):122-8.
PMID: 18537641
Ion channels are at present the third biggest target class in drug discovery. Primary research is continually uncovering potential new ion channel targets in indications such as cancer, diabetes and...
16.
Trivedi S, Dekermendjian K, Julien R, Huang J, Lund P, Krupp J, et al.
Assay Drug Dev Technol
. 2007 Dec;
6(2):167-79.
PMID: 18078380
Ion channels are challenging targets in the early phases of the drug discovery process, especially because of the lack of technologies available to screen large numbers of compounds in functionally...
17.
Ahmad S, Dahllund L, Eriksson A, Hellgren D, Karlsson U, Lund P, et al.
Hum Mol Genet
. 2007 Jun;
16(17):2114-21.
PMID: 17597096
The general lack of pain experience is a rare occurrence in humans, and the molecular causes for this phenotype are not well understood. Here we have studied a Canadian family...
18.
Gustafsson A, Ingelman-Sundberg H, Dzabic M, Awasum J, Nguyen K, Ostenson C, et al.
FASEB J
. 2004 Dec;
19(2):301-3.
PMID: 15572434
There is little information available concerning the link between the ryanodine (RY) receptors and the downstream Ca(2+) signaling events in beta-cells. In fura-2 loaded INS-1E cells, activation of RY receptors...